News - Page 10 of 35 - MaRS Innovation

Triphase Accelerator Corporation initiates phase I study of marizomib and bevacizumab in patients with Glioblastoma

TORONTO and SAN DIEGO, (April 22, 2015) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced that it has initiated a Phase I proof-of-concept clinical study of marizomib. The study is evaluating an intravenous (IV) formulation of marizomib, a novel and highly potent proteasome inhibitor, in combination with bevacizumab (Avastin®) in patients with glioblastoma, the most common and aggressive malignant primary brain tumor. The study is recruiting and enrolling patients at ... Read more

Onyx Motion’s digital coach Swish featured on Canada AM

UTEST company Onyx Motion's lead product, Swish -- a basketball virtual coach that currently works with Android Wear smartwatches to help basketball athletes to improve their shooting technique and emulate their heroes -- was featured on Canada AM this morning. Watch the clip of Onyx Motion's Swish on Canada AM, CTV's flagship morning show. Product feature plays after advertisements and begins at 1:40 mark. Think you've got an equally great software-based idea for a start-up? UTEST is currently recruiting for its fourth cohort. Tom ... Read more

Globe and Mail features UTEST company eQOL’s home dialysis technology

"When Binh Nguyen, then a graduate student in biomedical engineering at the University of Toronto, was working in the renal engineering department of a local hospital, he was struck by what he felt was a suboptimal setup for dialysis treatment," writes Jordana Dixon in "Health startup helps patients become more independent," for the Globe and Mail on April 13, 2015. eQOL Inc. is a University of Toronto and MaRS Innovation start-up company that participated in and graduated from the University of Toronto ... Read more

How to get accepted into the UTEST start-up incubator: Drive and differentiation

UTEST is now accepting applications to Cohort 4 Editor's note: As of today, the University of Toronto Early-Stage Technology (UTEST) program, which MaRS Innovation co-directs with the University of Toronto, is accepting applications for Cohort 4. The full application is available on the UTEST website.  In meantime, it's our pleasure to reprint Brianna Goldberg's "day-in-the-life-of-an-entrepreneur" feature on Cohort 3 company Nvest, published for U of T News. Jackie Yan focuses on tweaking his PowerPoint slide deck despite the chaos unfolding around him. Near the ... Read more

Smartphones and mobile tablets becoming mainstays for clinicians

VitalHub's partnership with Microsoft and Intel for Seattle Children's Hospital pilot and British Columbia contracts featured in Canadian Healthcare Technology "As hospital invest continue to invest in mobile solutions, doctors and nurses are more likely to be texting on their smartphones or swiping their fingers across a tablet PCs than tapping away on desktop computers," Dianne Daniel writes in the April 2015 issue of Canadian Healthcare Technology in an article titled, "Smartphones and mobile tablets are becoming essential tools for clinicians" ... Read more

UTEST company Nvest is bringing accountability to investment recommendations

Nvest, a University of Toronto company, is gaining traction as a financial technology (or fintech) start-up to watch. Nvest is part of the third UTEST cohort, which is an early-stage technology incubator program co-directed by MaRS Innovation and U of T (read more about the UTEST program in our portfolio section). In the last month, Nvest has been profiled in both TechVibes and Investment Executive as a company to watch both as a social network for stock picking and as a tool ... Read more

Sunnybrook forms new industry partnership to advance WaveCheck technology

Co-development agreement, brokered by MaRS Innovation, to advance ultrasound chemotherapy monitoring technology as clinical tool TORONTO (March 12, 2015) — Sunnybrook Health Sciences Centre and MaRS Innovation today announced a co-development agreement for WaveCheck, an ultrasound technology that transforms conventional equipment so that physicians can monitor a breast cancer tumour’s response to chemotherapy. This announcement was covered in Biotechnology Focus, Aunt Minnie.com (radiology blog), dotmed.com, Bio-Medicine.org, Bloomberg Business and Research Views. The partnership with GE Healthcare, brokered by MaRS Innovation, seeks to develop WaveCheck ... Read more

ChipCare closes oversubscribed $5 million series A financing

With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products. The Wall Street Journal's Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub ... Read more

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

Portfolio round-up: UTEST, Nvest and Whirlscape news

Sometimes there's so much happening with the MaRS Innovation portfolio that it's hard to stay on top of all the news. Here are a few UTEST program stories that we missed in February. UTEST was named to FundThrough.com's list of "6 Exciting Canadian Startup Accelerators to Watch in 2015." Program co-directors Mike Betts and Kurtis Scissons point out that UTEST does take an equity position in the incubated companies and does not run on a grant basis as mentioned in the ... Read more
Page 10 of 35« First...89101112...2030...Last »